相关实验视频

Updated: May 15, 2025

Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells

Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells

Published on: October 4, 2017

抑制SOD1三元化是一种针对ALS疾病的新型药物标

Tae-Gyun Woo¹, Jin Han¹, Yuju Kim¹

¹Institute of Rare Genetic Disease, PRG S&Tech Co., LTD, Busan, 46274, Republic of Korea.

Translational neurodegeneration

|May 11, 2025

概括

一种新的候选药物PRG-A-04有效地抑制了SOD1聚合在肌缩侧面硬化症 (ALS) 模型中. 这种化合物通过向突变SOD1.1,显示出治疗家族性和零星性ALS的前景.

科学领域:

神经科学是一个神经科学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

肌缩侧面硬化 (ALS) 是一种致命的神经退行性疾病,其特征是运动神经元死亡.
虽然10%的ALS病例是遗传的,但零星ALS的潜在机制,特别是SOD1聚合,仍然不清楚.
以前试图抑制SOD1聚合的尝试由于生物可用性较差而取得了有限的成功.

研究的目的:

开发和评估PRG-A-04,一种新型候选药物,旨在抑制ALS中的SOD1聚合.
评估PRG-A-04在临床前ALS模型中的体外和体内疗效.

主要方法:

使用神经细胞系和SOD1突变转基因小鼠 (SOD1 G93A-Tg) 来测试PRG-A-04.
使用寡合化试验,免疫光和点点试验分析了SOD1聚合.
在体内研究涉及口服,行为测试,组织学分析和微阵列分析.

主要成果:

PRG-A-04表现出高生物利用率和显著的血脑屏障透.
在SOD1^G93A-Tg小鼠中,口服PRG-A-04可减少SOD1聚合,保护神经元,并将寿命延长至3周.
在体外,PRG-A-04选择性地与突变SOD1结合,并通过三元体稳定剂诱导抑制聚合.

结论:

通过向突变SOD1聚合,PRG-A-04显示出对ALS的显著治疗潜力.
这些发现突显了针对三元SOD1作为家族性和零星性ALS的治疗策略的潜力.
PRG-A-04代表了ALS治疗的有希望的候选药物.

关键词:

肌缩侧面硬化症疾病肌缩侧面硬化症神经退行发生神经退行.非临床研究是非临床研究.在SOD1的聚合上,SOD1的聚合.这种SOD1三元体是SOD1三元体.

更多相关视频

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

相关概念视频

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...